Malignant astrocytoma in elderly patients: where do we stand?
نویسندگان
چکیده
PURPOSE OF REVIEW Age is inversely correlated with clinical outcome and a strong prognostic factor for the course of most primary brain tumors including malignant astrocytoma, i.e. anaplastic astrocytoma and glioblastoma. We here review available clinical outcome data and discuss future directions of clinical research. RECENT FINDINGS The standard of care in patients with malignant astrocytoma above the range of 65-70 years was considered radiotherapy, preferentially using a hypofractionated regimen (15 × 2.66 Gy). Two phase III clinical trials, the NOA-08 and Nordic trials, demonstrated that temozolomide (TMZ) therapy alone was not inferior to radiotherapy alone, and methylation of the O-methylguanine-DNA-methyltransferase (MGMT) gene promoter was predictive with a methylated MGMT promoter indicating a benefit from TMZ chemotherapy. Ongoing clinical trials in this patient population include the National Cancer Institute of Canada/European Organisation for Research and Treatment of Cancer intergroup trial, investigating the combination of hypofractionated radiotherapy and TMZ chemotherapy, and the Swiss ARTE trial, investigating the combination of bevacizumab and hypofractionated radiotherapy. Recent translational studies indicate that prognostically favorable factors in malignant astrocytoma from younger patients are virtually absent in the elderly. SUMMARY Current standard of care for elderly patients with malignant astrocytoma involves a treatment strategy based on the MGMT gene promoter methylation status. The role of combined radiotherapy and TMZ chemotherapy and a potential role for the addition of anti-VEGF therapy to radiotherapy are currently addressed in ongoing trials. The lack of favorable prognostic factors in tumor tissue might in part explain the poorer clinical outcome of elderly patients.
منابع مشابه
Adhesive small bowel obstruction: where do we stand now?
Adhesive small bowel obstruction (ASBO) is one of the most frequently encountered disorders in Emergency Surgery Departments worldwide without negligible hospital admission rates and social costs (1,2). Notwithstanding significant improvements in techniques and materials, intra-abdominal adhesions following abdominal surgery still represent a major unsolved and debated issue harbouring challeng...
متن کاملEvidence - based CAM: Where does it stand?
In the past 10 years evidence - based medicine (EBM) has developed well in all aspects of allopathic medicine giving a new dimension to patient care including cost reduction and attention to medical ethics. With the public and medical community return to complementary and alternative medicine (CAM) in the last two decades there has been a call for evidence - based CAM … in the same way that all...
متن کاملSURVIVAL IN PATIENTS WITH MALIGNANT GLIOMAS OF THE BRAIN
The present retrospective study was designed to analyze factors with prognostic values a) within, and b) significantly associated with, short-term (12months or less) and long-term (more than 24 months) survival times, i n 72 consecutive patients treated for malignant gliomas. Among 41 (57%) short-term surviving patients, the absence of both aphasia and motor deficit (as initial presenting ...
متن کاملTemozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
BACKGROUND Radiotherapy is the standard care in elderly patients with malignant astrocytoma and the role of primary chemotherapy is poorly defined. We did a randomised trial to compare the efficacy and safety of dose-dense temozolomide alone versus radiotherapy alone in elderly patients with anaplastic astrocytoma or glioblastoma. METHODS Between May 15, 2005, and Nov 2, 2009, we enrolled pat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Current opinion in neurology
دوره 26 6 شماره
صفحات -
تاریخ انتشار 2013